

---

**5 June 2018**  
**Australian Securities Exchange (ASX) Announcement**

## **Organ-on-Chip: a Growing MedTech Market Opportunity for Sensera MEMs**

### **Highlights:**

- **Sensera secures Harvard University's Wyss Institute for Biologically Inspired Engineering as a revenue-generating client in the precision medicine and personalised health sector**
- **Sensera is supporting the industry's growing applications in 'organs-on-chips', where MEMS devices accurately mimic functions of the human body, including the respiratory, circulatory and digestive systems**
- **The Company now has multiple customers engaged in the development of organ-on-a-chip microfluidic devices**

Sensera Limited (ASX: SE1, "Sensera" or "the Company"), an Internet of Things (IoT) solution provider that delivers sensor-based products transforming real-time data into meaningful information, action and value, is pleased to advise of revenue-generating new customer traction in the Medtech sector for its microdevices business.

Harvard University's Wyss Institute for Biologically Inspired Engineering is now working with Sensera to adapt the Company's MicroElectroMechanical Systems (MEMS) technology for new applications in bioengineering. A key outcome will be the creation of microfluidic devices, which mimic the functions of living human organs, including the lung, intestine, kidney, skin, bone marrow and blood-brain barriers.

Dr. Richard Novak, Senior Staff Engineer at Harvard University's Wyss Institute, said:

*"Sensera is a key partner providing critical microdevice component fabrication, which enables our growing applications in precision medicine and personalised health.*

*"These microchips, called 'organs-on-chips', offer a potential alternative to traditional animal testing. Each organ-on-chip comprises a polymeric membrane that contains hollow channels lined by living human cells. These hollow, microfluidic channels carry fluids in a way that accurately mimics various functions of the human body, including the respiratory, circulatory and digestive systems.*

*"Mechanical forces can be applied to mimic the physical microenvironments of living organs, including breathing motions in the lung and peristalsis-like deformations in the intestine. Sensera has been able to deliver consistent quality while meeting challenging specifications."*

For the Wyss Institute and other customers, Sensera provides moulds to manufacture the polymeric membranes that are assembled in the organ-on-a-chip microfluidic devices. These moulds are a key component in allowing these living, micro-engineered environments to recreate the natural physiology and mechanical forces that cells experience within the human body.

Sensera CEO and MD, Ralph Schmitt, said:

*"Manufacturing these moulds is a new challenge for us. We've had to adapt our traditional MEMS processes and implement a very stringent quality management system that meets the demands of biomedical applications. Through our collaboration with the Wyss Institute, we now have multiple customers engaged in this technology."*

*"These types of MEMS-based products are exciting. It's a high-growth market space in precision medical technology. We are pleased to be able to offer such unique capabilities for customers impacting the health of people worldwide."*

The success of Sensera's involvement in the microfluidic device market is supported by the fact that it is ISO 9001 certified and is working towards its ISO 13485 certification.

**For more information, please contact:**

**Ralph Schmitt**  
Chief Executive Officer  
+1 978 606 2600  
[info@sensera.com](mailto:info@sensera.com)

**Tim Dohrmann**  
Investor Relations  
+61 468 420 846  
[tim@nwrcommunications.com.au](mailto:tim@nwrcommunications.com.au)

**About Sensera Limited (ASX: SE1):**

Sensera is an Internet of Things (IoT) solution provider that delivers sensor-based products transforming real-time data into meaningful information, action and value. The company designs and manufactures hardware and software across the vertical technology spectrum from unique structures as MicroElectroMechanical Systems (MEMS) and sensors, as well as wireless networked systems and software that when combined, drive an entire IoT platform solution.

Shares in Sensera Limited (ASX: SE1) are traded on the Australian Securities Exchange (ASX). For more information, please visit our website: [www.sensera.com](http://www.sensera.com).

Any forward-looking statements in this announcement are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management.